Literature DB >> 34532139

Screening potential prognostic biomarkers for portal vein emboli in patients with hepatocellular carcinoma.

Weijie Zhou1, Da Lang Fang2, Yongfei He3.   

Abstract

BACKGROUND: The formation of portal vein tumor thrombus (PVTT) is closely related to the prognosis of patients with hepatocellular carcinoma (HCC). However, the mechanisms by which PVTTs form and the biomarkers involved are still little understood.
METHODS: The Genome Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases were used to obtain transcriptome data from normal tissue, HCC tissue, primary tumors (PTs) of HCC, and paired PVTT tissue. Differentially expressed genes (DEGs) in PTs and PVTTs were analyzed. The differentially expressed immune genes were further investigated in terms of their prognostic significance, immune infiltration, function. Finally, we explored the relationship between risk scores and drug sensitivity based on the R package.
RESULTS: In the two datasets, there were 458 DEGs identified in the PT and PVTT tissues, of which, 58 were immune-related genes. The differentially expressed immune genes may promote the progression of PVTT by participating in the regulation of non-cellular components such as the extracellular matrix, inflammatory factors, and chemokines. Furthermore, the immune genes KDR, AKT3, FCGR2B, KIAA1429, and TPT1 were correlated with the prognosis of HCC in patients with PVTT. Using this data, a model was constructed to predict the prognosis of patients, thus allowing for the identification of high- and low-risk patients.
CONCLUSIONS: This study demonstrated that immune-related genes may be involved in the regulation of the extracellular matrix and acellular components, and subsequently, in the formation of PVTT. These five genes KDR, AKT3, FCGR2B, KIAA1429, and TPT1 may be potential prognostic biomarkers and treatment targets for HCC patients with PVTT. 2021 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Hepatocellular carcinoma (HCC); biomarker; immune; portal vein tumor thrombus (PVTT)

Year:  2021        PMID: 34532139      PMCID: PMC8421875          DOI: 10.21037/jgo-21-433

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  36 in total

1.  Extracellular vesicle-packaged HIF-1α-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells.

Authors:  Fei Chen; Jianing Chen; Linbin Yang; Jiang Liu; Xiaoqian Zhang; Yin Zhang; Qingqiang Tu; Dong Yin; Dechen Lin; Ping-Pui Wong; Di Huang; Yue Xing; Jinghua Zhao; Mengfeng Li; Qiang Liu; Fengxi Su; Shicheng Su; Erwei Song
Journal:  Nat Cell Biol       Date:  2019-04-01       Impact factor: 28.824

Review 2.  Contributions of Fibroblasts, Extracellular Matrix, Stiffness, and Mechanosensing to Hepatocarcinogenesis.

Authors:  Aveline Filliol; Robert F Schwabe
Journal:  Semin Liver Dis       Date:  2019-06-21       Impact factor: 6.115

3.  Genetic polymorphisms of proangiogenic factors seem to favor hepatocellular carcinoma development in alcoholic cirrhosis.

Authors:  Mariana V Machado; André Janeiro; Gabriel Miltenberger-Miltenyi; Helena Cortez-Pinto
Journal:  Eur J Gastroenterol Hepatol       Date:  2014-04       Impact factor: 2.566

4.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

5.  Combination of osteopontin with peritumoral infiltrating macrophages is associated with poor prognosis of early-stage hepatocellular carcinoma after curative resection.

Authors:  Wenwei Zhu; Lei Guo; Bo Zhang; Lili Lou; Zhenghai Lin; Xiaodong Zhu; Ning Ren; Qiongzhu Dong; Qinghai Ye; Lunxiu Qin
Journal:  Ann Surg Oncol       Date:  2013-12-24       Impact factor: 5.344

6.  Hsa_circ_0003998 promotes epithelial to mesenchymal transition of hepatocellular carcinoma by sponging miR-143-3p and PCBP1.

Authors:  Li-Na Song; Guang-Lei Qiao; Jian Yu; Chun-Mei Yang; Ying Chen; Zhou-Feng Deng; Li-Hua Song; Li-Jun Ma; Hong-Li Yan
Journal:  J Exp Clin Cancer Res       Date:  2020-06-17

Review 7.  Immunotherapy for hepatocellular carcinoma: Current and future.

Authors:  Michael P Johnston; Salim I Khakoo
Journal:  World J Gastroenterol       Date:  2019-06-28       Impact factor: 5.742

8.  Integrative molecular analysis of metastatic hepatocellular carcinoma.

Authors:  Dongfang Wang; Yanjing Zhu; Jing Tang; Qiuyu Lian; Guijuan Luo; Wen Wen; Michael Q Zhang; Hongyang Wang; Lei Chen; Jin Gu
Journal:  BMC Med Genomics       Date:  2019-11-13       Impact factor: 3.063

9.  KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3.

Authors:  Tian Lan; Hui Li; Delin Zhang; Lin Xu; Hailing Liu; Xiangyong Hao; Xiaokai Yan; Haotian Liao; Xiangzheng Chen; Kunlin Xie; Jiaxin Li; Mingheng Liao; Jiwei Huang; Kefei Yuan; Yong Zeng; Hong Wu
Journal:  Mol Cancer       Date:  2019-12-19       Impact factor: 27.401

10.  CD86⁺/CD206⁺, Diametrically Polarized Tumor-Associated Macrophages, Predict Hepatocellular Carcinoma Patient Prognosis.

Authors:  Pingping Dong; Lijie Ma; Longzi Liu; Guangxi Zhao; Si Zhang; Ling Dong; Ruyi Xue; She Chen
Journal:  Int J Mol Sci       Date:  2016-03-01       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.